Related references
Note: Only part of the references are listed.Parathyroid Hormone (PTH)-Induced Bone Gain Is Blunted in SOST Overexpressing and Deficient Mice
Ina Kramer et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2010)
Two Doses of Sclerostin Antibody in Cynomolgus Monkeys Increases Bone Formation, Bone Mineral Density, and Bone Strength
Michael S. Ominsky et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2010)
Serum Sclerostin Levels Negatively Correlate with Parathyroid Hormone Levels and Free Estrogen Index in Postmenopausal Women
Faryal S. Mirza et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2010)
PTH and PTHrP signaling in osteoblasts
Nabanita S. Datta et al.
CELLULAR SIGNALLING (2009)
Primary hyperparathyroidism and the skeleton
Leif Mosekilde
CLINICAL ENDOCRINOLOGY (2008)
Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength
Xiaodong Li et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2008)
Control of Bone Mass and Remodeling by PTH Receptor Signaling in Osteocytes
Charles A. O'Brien et al.
PLOS ONE (2008)
Mechanical stimulation of bone in vivo reduces osteocyte expression of Sost/sclerostin
Alexander G. Robling et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
Effects of intermittent parathyroid hormone (PTH) administration on SOST mRNA and protein in rat bone
G. Silvestrini et al.
JOURNAL OF MOLECULAR HISTOLOGY (2007)
Bone density ligand, sclerostin, directly interacts with LRP5 but not LRP5G171V to modulate Wnt activity
Debra L. Ellies et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2006)
Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: A novel mechanism for hormonal control of osteoblastogenesis
T Bellido et al.
ENDOCRINOLOGY (2005)
Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling
XF Li et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist
RL van Bezooijen et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2004)
PTH differentially regulates expression of RANKL and OPG
JC Huang et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2004)
Mediators of the biphasic responses of bone to intermittent and continuously administered parathyroid hormone
RM Locklin et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2003)
Osteocyte control of bone formation via sclerostin, a novel BMP antagonist
DG Winkler et al.
EMBO JOURNAL (2003)
Catabolic effects of continuous human PTH (1-38) in vivo is associated with sustained stimulation of RANKL and inhibition of osteoprotegerin and gene-associated bone formation
YFL Ma et al.
ENDOCRINOLOGY (2001)
Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST)
W Balemans et al.
HUMAN MOLECULAR GENETICS (2001)
Share Paper
